Your browser doesn't support javascript.
loading
Prognostic factors in uterine adenosarcoma: subanalysis of the SARCUT study.
Mancari, Rosanna; Yusuf, Yildirim; Macuks, Ronalds; Achimas-Cadariu, Patriciu; Piek, Jurgen Martinus; Sperduti, Isabella; Corrado, Giacomo; Vizza, Enrico; Zapardiel, Ignacio.
Afiliação
  • Mancari R; Gynecologic Oncology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Yusuf Y; Gynecologic Oncology Department, Tepecik Training and Research Hospital, Izmir, Türkiye.
  • Macuks R; Latvian Oncology Center of Riga Eastern Clinical University Hospital, Riga, Latvia.
  • Achimas-Cadariu P; Gynecologic Oncology Department, Institute of Oncology Prof. Dr. I Chiricuta, Cluj-Napoca, Romania.
  • Piek JM; Gynecologic Oncology Department, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca, Romania.
  • Sperduti I; Gynecologic Oncology Department, Catharina Ziekenhuis Department of Gynecology, Eindhoven, Netherlands.
  • Corrado G; Unit of Biostatistical, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Vizza E; Gynecologic Oncology Unit, Department of Woman, Child and Public Health, Fondazione Policlinico Uni-versitario A. Gemelli IRCCS, Rome, Italy.
  • Zapardiel I; Gynecologic Oncology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Front Oncol ; 14: 1393707, 2024.
Article em En | MEDLINE | ID: mdl-38835369
ABSTRACT

Objective:

The purpose of the study was to analyse the role of prognostic factors on the risk of recurrence and overall survival of patients with uterine adenosarcoma.

Methods:

A retrospective international multicentre study involving 46 centres collected 32 cases of uterine adenosarcoma, and these cases were included in the present subanalysis. Clinical and demographic features and tumour characteristics were gathered, as well as information on treatment and relapse. Disease-free and overall survival were analysed.

Results:

The 5-year disease-free survival (DFS) was 85.3% and the 5-year overall survival (OS) rate was 89.5%. The risk factors significantly associated with overall survival were age (HR 1.09, 95% CI 1.03-1.15; p = 0.004) and FIGO stage II-III (HR 17.75, 95% CI 2.87-109.93; p = 0.002). Patients who experienced early relapse (within 12 months) had a tumour size >30 mm and advanced stage. The majority of recurred cases were treated with radiotherapy or surgery and obtained a good response rate.

Conclusion:

The most significant prognostic factors in uterine adenosarcoma were age and FIGO stage and, indirectly, tumour size at diagnosis. The use of secondary surgery and/or radiotherapy could help in prolonging the disease-free status of the patients.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália